Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE

NCT06661720 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT06661720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06661720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 3
Overall status
Recruiting
Start date
March 14, 2025
Completion date
November 30, 2037
Enrollment
1,040 (estimated)
Sites
425

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma, renal cell carcinoma (rcc), stage ii renal pelvis cancer ajcc v8, stage iii renal pelvis cancer ajcc v8